{"id":"NCT04225260","sponsor":"Galderma R&D","briefTitle":"Long-term Treatment of Moderate to Severe Glabellar Lines and Lateral Canthal Lines","officialTitle":"A Multicenter, Open-Label Study to Evaluate the Safety of QM1114-DP for the Long-term Treatment of Moderate to Severe Glabellar Lines and Lateral Canthal Lines","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2020-01-27","primaryCompletion":"2021-04-12","completion":"2021-05-21","firstPosted":"2020-01-13","resultsPosted":"2023-06-18","lastUpdate":"2023-06-18"},"enrollment":902,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Glabellar Lines","Lateral Canthal Lines"],"interventions":[{"type":"BIOLOGICAL","name":"botulinum toxin neuromodulator","otherNames":["QM1114-DP"]}],"arms":[{"label":"QM1114-DP in the LCL and the GL areas","type":"EXPERIMENTAL"}],"summary":"This is a phase 3, multicenter, open-label study to evaluate the safety of QM1114-DP for the long term treatment of moderate to severe Glabellar (Frown) Lines (GL) and Lateral Canthal Lines (Crow's Feet and LCL).","primaryOutcome":{"measure":"Percentage of Subjects Who Achieve Grade/Level 0 or 1 on the GL Investigator Scales at Maximum Frown","timeFrame":"Week 4","effectByArm":[{"arm":"QM1114-DP in the GL","deltaMin":769,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":null,"exclusionCount":4},"locations":{"siteCount":30,"countries":["United States","Puerto Rico"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":23,"n":902},"commonTop":["Injection site Pain","Injection site bruising","Headache","COVID-19","Hypertension"]}}